FindTrial
Sign In

The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19): A medical records based retrospective cohort study

The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19): A medical records based retrospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033798
Enrollment
Unknown
Registered
2020-06-12
Start date
2020-06-12
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

convalescent plasma therapy group:no
non-convalescent plasma therapy group:no

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Meets COVID-19 diagnosis criteria of WHO

Exclusion criteria

Exclusion criteria: 1. age <18 years; 2. pregnant; 3. length of hospital <24 hours; 4. insufficient clinical information; 5. serious complications not directly related to the COVID0-19 (including but not limited to surgical emergencies, intracranial hemorrhage, multiple injuries, etc.); 6. dead within 24 hours from admission.

Design outcomes

Primary

MeasureTime frame
all cause in-hospital mortality;—

Secondary

MeasureTime frame
serum SARS-CoV-2 RNA load;serum antibody titers of IgG and IgM;—

Countries

China

Contacts

Public ContactMinghao Fang

Emergency / Intensive Care Department of Tongji Hospital

fangmhtj@163.com+86 15071157405

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026